Drug agents need to respond flexibly to new medical reforms under the new policy

In the face of the medical system reform, drug agents are affected by the whole situation: they must initially establish a national basic drug system, and must also speed up the construction of the basic medical security system; on the one hand, they should improve the primary health care service system, and on the other hand must promote Public hospital reform pilot. A series of reforms are both blessings and curses for drug agents. The evils of blessings and blessings, the blessings of misfortune, and the blessings of evil can be transformed into one another. The impact of the new medical reform on drug agents has become prominent. One possibility is to conduct a new round of shuffling.

Facing the ever-changing market for pharmaceutical investment, and the “fixed-point system” for essential medicines for medical reform, it will inevitably increase industry concentration, and there will certainly be a lot of SMEs who are seriously injured or even paralyzed. The new medical reform will promote the strength of pharmaceutical agents. Big companies move closer, and at the same time, they further subdivide the agency industry. There are often opportunities in the transformation of things. Once they are caught and they are out of control, how medicine agents can survive under the new medical reform depends on how they find and seize opportunities.

Analyze the new medical reform plan and come to the conclusion that the future of drug agents will not be too good. The reason is that the basic medicines are subject to tendered production or centralized procurement and direct distribution by the state, reducing the intermediate links, and formulating the retail price on the basis of a reasonable determination of the profits of the pharmaceutical investment enterprises' production links. This means that the unreasonable profits of the intermediate links will be greatly reduced, and the number of drug agents as one of the intermediate links will also be greatly reduced. Although the impact of the new healthcare reform on agents is inevitable, it is unlikely that pharmaceutical agents will completely fade out of intermediary agents.

For a long time, pharmaceutical companies did not have their own marketing team. They were drug agents who formed their own teams to promote drugs. The products most affected by centralized procurement are products that are listed in the basic drug list, and more self-financed drugs that are out of the list still require the efforts of drug agents to open up and promote the market. If drug dealers can expand their business from the above three aspects, perhaps the evil will become a good thing, and the impact will be minimized.